Is it possible to identify early predictors of the future cost of chronic arthritis? the VErA project

Fundamental and Clinical Pharmacology

Volumn 23, Issue 1, 2009, Pages 105-113

  Flipon, E ^a,b   Brazier, M ^a,b   Clavel, G ^a   Boumier, P ^a   Gayet, A ^c   Le Loet X ^c   Fardellone, P ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Clinical Pharmacy Laboratory   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Clinical and biological predictors; Costs; Inflammatory arthritis; Rheumatoid arthritis

Indexed keywords

RHEUMATOID FACTOR;

ADULT; AGED; ARTHRALGIA; ARTICLE; COST OF ILLNESS; ECONOMIC ASPECT; FEMALE; GRIP STRENGTH; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTOR VARIABLE; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; COST OF ILLNESS; FEMALE; FORECASTING; FRANCE; HEALTH CARE COSTS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PAIN; PROSPECTIVE STUDIES; QUESTIONNAIRES; RHEUMATOID FACTOR; YOUNG ADULT;

EID: 61349105953     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00645.x     Document Type: Article

References (35)

1. Fautrel B., Guillemin F. Cost of illness studies in rheumatic diseases. Curr. Opin. Rheumatol. (2002) 14 121 126.
2. Guillemin F., Durieux S., Daures J.P. et al. Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists. J. Rheumatol. (2004) 31 1297 1304.
3. Michaud K., Messer J., Choi H.K. et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. (2003) 48 2750 2762.
4. Rat A.C., Boissier M.C. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine (2004) 71 518 524.
5. Cooper N.J. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) (2000) 39 28 33.
6. Arnett F.C., Edworthy S.M., Bloch D.A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. (1988) 31 315 324.
7. van der Heijde D.M., van 't Hof M.A., van Riel P.L. et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann. Rheum. Dis. (1990) 49 916 920.
8. SPSS Inc. SPSS for Windows 12.0. SPSS Inc, Chicago, IL, 2003. Available at: http://www.spss.com.
9. Verstappen S.M., Verkleij H., Bijlsma J.W. et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann. Rheum. Dis. (2004) 63 817 824.
10. Maravic M., Berge C., Daures J.P. et al. Practices for managing a flare of long-standing rheumatoid arthritis: survey among French rheumatologists. Clin. Exp. Rheumatol. (2005) 23 36 42.
11. Maravic M., Berge C., Daures J.P. et al. Survey of practices regarding management of early rheumatoid arthritis by rheumatologists in France. Clin. Exp. Rheumatol. (2004) 22 319 327.
12. Mitchell K.L., Pisetsky D.S. Early rheumatoid arthritis. Curr. Opin. Rheumatol. (2007) 19 278 283.
13. Pisu M., James N., Sampsel S., Saag K.G. The cost of glucocorticoid- associated adverse events in rheumatoid arthritis. Rheumatology (Oxford) (2005) 44 781 788.
14. Huscher D., Merkesdal S., Thiele K. et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann. Rheum. Dis. (2006) 65 1175 1183.
15. Kavanaugh A. Economic issues with new rheumatologic therapeutics. Curr. Opin. Rheumatol. (2007) 19 272 276.
16. van Jaarsveld C.H., Jacobs J.W., Schrijvers A.J. et al. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br. J. Rheumatol. (1998) 37 837 847.
17. Griffiths R.I., Bar-Din M., MacLean C. et al. Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients. Ther. Apher. (2001) 5 92 104.
18. Newhall-Perry K., Law N.J., Ramos B. et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J. Rheumatol. (2000) 27 1156 1163.
19. Leardini G., Salaffi F., Montanelli R. et al. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin. Exp. Rheumatol. (2002) 20 505 515.
20. Ruof J., Hulsemann J.L., Mittendorf T. et al. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources. Ann. Rheum. Dis. (2003) 62 544 549.
21. Puolakka K., Kautiainen H., Mottonen T. et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. (2005) 52 36 41.
22. Fautrel B., Woronoff-Lemsi M.C., Ethgen M. et al. Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France. Joint Bone Spine (2005) 72 550 556.
23. Bansback N.J., Regier D.A., Ara R. et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs (2005) 65 473 496.
24. Merkesdal S., Ruof J., Huelsemann J.L. et al. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data. Arthritis Rheum. (2005) 53 234 240.
25. Puolakka K., Kautiainen H., Pekurinen M. et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann. Rheum. Dis. (2006) 65 899 904.
26. Clake A.E., Zowall H., Levinton C. et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J. Rheumatol. (1997) 24 1051 1060.
27. Insee. Insee: French databases. Available at: http://www.insee.fr/fr/ themes/theme.asp?theme=3 (last accessed 22 October 2008).
28. Yelin E., Trupin L., Katz P. et al. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum. (2003) 48 3046 3054.
29. Rosery H., Bergemann R., Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics (2005) 23 243 257.
30. Hallert E., Husberg M., Jonsson D. et al. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology (Oxford) (2004) 43 1374 1382.
31. Puolakka K., Kautiainen H., Mottonen T. et al. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann. Rheum. Dis. (2005) 64 130 133.
32. Schellekens G.A., de Jong B.A., van den Hoogen F.H. et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. (1998) 101 273 281.
33. Clavel G., Bessis N., Boissier M.C. Recent data on the role for angiogenesis in rheumatoid arthritis. Joint Bone Spine (2003) 70 321 326.
34. Ballara S., Taylor P.C., Reusch P. et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. (2001) 44 2055 2064.
35. Sone H., Sakauchi M., Takahashi A. et al. Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity. Life Sci. (2001) 69 1861 1869.